Nathalie LeVasseur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3631742/publications.pdf

Version: 2024-02-01

21 213 7 14 papers citations h-index g-index

times ranked

citing authors

docs citations

all docs

#	Article	lF	CITATIONS
1	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study. Clinical Breast Cancer, 2022, 22, e74-e79.	2.4	8
2	Optimising weight-loss interventions in cancer patientsâ€"A systematic review and network meta-analysis. PLoS ONE, 2021, 16, e0245794.	2.5	11
3	Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients. Breast Cancer Research and Treatment, 2021, 187, 167-176.	2.5	1
4	Examining social media peer support and improving psychosocial outcomes for young women with breast cancer Journal of Clinical Oncology, 2021, 39, 162-162.	1.6	3
5	Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 529-536.	2.5	37
6	Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy. Oncologist, 2020, 25, 212-217.	3.7	7
7	Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?. British Journal of Cancer, 2019, 121, 1-2.	6.4	2
8	Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database. Clinical Breast Cancer, 2019, 19, e683-e689.	2.4	12
9	Unnecessary Variation in Practice: How to Improve Cancer Care through Pragmatic Trials. Current Oncology, 2018, 25, 263-264.	2.2	1
10	Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancerâ€"A Survey of Oncology Nurses and Physicians. Current Oncology, 2018, 25, 298-304.	2.2	24
11	Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Research and Treatment, 2018, 171, 607-620.	2.5	37
12	Can We Hang Our Hats on One Percent?. Oncologist, 2018, 23, 642-644.	3.7	0
13	Perceptions of Vascular Access for Intravenous Systemic Therapy and Risk Factors for Lymphedema in Early-Stage Breast Cancerâ€"A Patient Survey. Current Oncology, 2018, 25, 305-310.	2.2	18
14	Whole genome sequencing in metastatic breast cancer: Lessons learned from the BC Cancer personalized oncogenomics program Journal of Clinical Oncology, 2018, 36, 12065-12065.	1.6	1
15	Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?. British Journal of Cancer, 2017, 117, 157-158.	6.4	1
16	Comparing outcomes of neoadjuvant endocrine therapy versus chemotherapy in ER-positive breast cancer: Results from a prospective institutional database Journal of Clinical Oncology, 2017, 35, 581-581.	1.6	1
17	Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews, 2016, 50, 183-193.	7.7	39
18	Weight control strategies in breast cancer patients: A systematic review Journal of Clinical Oncology, 2016, 34, 179-179.	1.6	0

#	Article	IF	CITATIONS
19	Optimal weight control strategies in cancer patients: A systematic review Journal of Clinical Oncology, 2016, 34, 10109-10109.	1.6	0
20	Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?. Minerva Chirurgica, 2015, 70, 181-93.	0.8	6
21	Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer. Breast Cancer Research and Treatment, 0, , .	2.5	4